Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer

Learn more about:
Related Clinical Trial
A Phase 1, Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas AMG 319 Lymphoid Malignancy FIH Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies Tandem Auto-Allo Transplant for Lymphoma Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas CD4CAR for CD4+ Leukemia and Lymphoma Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma A Study for Patients With Non-Hodgkin’s Lymphomas High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma Allo-HSCT as First-line Consolidation in High-risk PTCL A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low ( T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL) Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL) ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia A Multicenter Clinical Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin in Patients With Relapsed/Refractory CD38 Positive PTCL-NOS, Angioimmunoblastic T-cell Lymphoma AITL and Other Nodal Lymphomas of T Follicular Helper Cells Origin Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin’s Lymphoma HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma Gemcitabine in NK/T Cell Lymphoma A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma Trial of Endostar Combined With CHOPT for T Cell Lymphoma Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Brief Title

Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer

Official Title

Collection of Blood, Bone Marrow and Tissue Samples for the Investigation of the Human Immune Response, Lymphoma Biology and HTLV-1 Infection

Brief Summary

      This protocol is being submitted to consolidate, update, and expand two previously approved
      protocols (77-C-0066 and 82-C-0044) into a single protocol. The purpose of this study is to
      examine the factors involved in the regulation of the immune system of healthy individuals
      and to define the abnormalities in this regulation that underlies the immunological disorders
      of patients with a variety of immunodeficiency and malignant disorders. The studies will
      include the ex vivo phenotypic and functional analysis of the network of cells involved in
      humoral and cellular immune responses, and in vivo testing for the capacity to make
      delayed-type hypersensitivity and humoral responses following immunization with a variety of
      antigens. Individuals to be studied will include patients with a variety of malignancies and
      patients with primary and secondary immunodeficiency disorders. Selected family members or
      family members known to be genetic carriers of certain immunodeficiency diseases as well as
      normal, unrelated individuals will also be studied. A small number of procedures will be used
      including analysis of blood obtained by phlebotomy, apheresis, skin testing and recall
      antigens and immunization to assess humoral immunity.

Detailed Description


        -  The evaluation of the cells of the immune system and HTLV-1 infection has been a central
           focus of the Metabolism Branch for the past 30 years.

        -  Blood obtained by apheresis or blood drawing, skin biopsies and other tissues will be
           evaluated for abnormalities related to immunity, HTLV-1 infection and the immune system.

        -  Advances in the characterization of acquired genetic changes in tumor samples has

      led to insights for the development of targeted therapy of malignancy


        -  To characterize the molecular biology and immunological features as well as the clinical
           course of individuals with suspected or known disorders of the immune system or cancer

        -  To define the nature of the immunological, genetic and epigenetic abnormalities in the
           cells of patients with immunodeficiency diseases associated with infections and/or a
           high incidence of malignancy and in patients with cancer.

        -  To obtain whole blood, plasma and leukocytes, as well as skin, lymph node and bone
           marrow biopsies on patients with immunodeficiency or cancer to investigate the immune


        -  Subjects with cancer.

        -  Subjects with immunodeficiency.

        -  Subjects with HTLV-1 infection.


      -This is a natural history study that permits tissue acquisition for analysis of the immune
      system and HTLV-1 infection.

Study Type


Primary Outcome

Create Biobank


T-cell Lymphoma

Study Arms / Comparison Groups

Description:  Suspected or known disorder of the immune system or cancer; or, known or potential carrier of autoimmune disorder or immunodeficiency disease.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

June 7, 1997

Eligibility Criteria


        Participants must meet at least one of these criteria:

        Have suspected or known disorder of the immune system or cancer

        Be a known or potential carrier of autoimmune disorder or immunodeficiency disease.
        Specific disorders may include but are not limited to:

          -  X-linked (severe combined immunodeficiency)

          -  Autosomal recessive SCID

          -  X-linked CD40 ligand deficiency

          -  Common variable immunodeficiency

          -  Ataxia-telangiectasia

          -  Wiskott Aldrich syndrome

          -  DiGeorge syndrome

          -  Infection with HTLV-1

        Age greater than or equal to 18 years.

        Participant must be able to understand and sign informed consent.

        Participants who will undergo apheresis must have hematocrit greater than 28%, and platelet
        count greater than 50,000.

        Subjects for whom apheresis is desired but whose counts are lower than those above must be
        evaluated and approved by a Department of Transfusion Medicine consult physician.

        Weight greater than 25 kg is necessary for apheresis.


        Overall Exclusion Criteria:

        Pregnant women will not be eligible for any aspect of this protocol.

        Exclusion Criteria for Apheresis Alone:

        Any diagnosed medical condition which may be worsened by the apheresis procedure.
        Specifically the participant should not have any of the following:

          1. Congestive Heart Failure

          2. History of angina

          3. Severe hypotension (at the discretion of the participant's physician, the apheresis
             staff and the attending physician from the Department of Transfusion Medicine (DTM)
             per DTM Standard Operating Policies.)

          4. Poorly controlled hypertension (average baseline blood pressure greater than 160/90)

          5. History of a coagulation protein disorder.

        Pediatric patients (less than 18 years) will not undergo apheresis.




18 Years - N/A

Accepts Healthy Volunteers



Kevin C Conlon, M.D., (240) 760-6050, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

National Cancer Institute (NCI)

Study Sponsor

Kevin C Conlon, M.D., Principal Investigator, National Cancer Institute (NCI)

Verification Date

January 11, 2022